Mylan to pay $465 mn over EpiPen overcharges to Medicaid

Mylan will pay $465 million to resolve accusations from some regulators that it overbilled the federal Medicaid program for the EpiPen allergy medication, the drugmaker announced Friday. The settlement with the Department of Justice and some other regulators resolves questions about Mylan's classification of EpiPen as a generic drug, the drugmaker said. Mylan said it did not admit fault in the agreement.

View post:
Mylan to pay $465 mn over EpiPen overcharges to Medicaid